Personalized Medicine Podcast

Welcome to the next episode of the Personalized Medicine Podcast. In this episode, our host Aradhana sat down for a conversation with Dr Ali Aghebat Rafat, Scientist at Tilibit Nanosystems. Aradhana and Ali discussed DNA nanostructures, DNA self-assembly, barcoding, biochips and their potential applications in Personalized Medicine.Tune in to this episode to learn more about: ◦ Tilibit Nanosystems and their mission ◦ Application areas of DNA origami in diagnostics ◦ What is DNA Paint ◦ A day in a life of a start-up scientist ◦ Role of nucleic acid nanostructures in Personalized Medicine ◦ The outlook on the future of DNA origami technology

Welcome to the next episode of the Personalized Medicine Podcast. In this episode, our host Aradhana talked to Martin Rabel, the Field Application Scientist at Precision Nanosystems, about nanoparticles, microfluidics, gene delivery in the context of personalized medicine.Tune in to this episode to learn more about: ◦ Precision Nanosystems and their mission ◦ Role of nanoparticles and microfluidics in Personalized Medicine ◦ Next-Gen microfluidics technologies ◦ Application of nanoparticles in pharmaceutical applications ◦ Challenges in developing RNA-based lipid nanoparticles ◦ Role of regulatory bodies in implementation of personalized medicine approaches ◦ The outlook on the future of personalized medicineGet in touch with Martin: ◦ LinkedIn: Martin Rabel ◦ Twitter: @rabel_martin

In this episode we dive deep into the world of structural biology. We discuss the role of cryogenic electron microscopy in the development of precision medicines with the founder and CEO of Gandeeva Therapeutics, Dr. Sriram Subramaniam. Cryo-EM opened a new way to study drug-target interactions and is changing the way we develop new therapies.Tune into our interview with Sriram to learn more about: ◦ The founding story of Gandeeva Therapeutics ◦ The evolution of Cryo-EM technology ◦ Application of Cryo-EM in drug discovery ◦ Advantages of Cryo-EM over crystallography im mapping protein structures ◦ Making sense of experimental data with AI and machine learning ◦ The future of personalized medicine and role of structural biology in it ◦ Sriram's advice for budding life science entrepreneurs

In this next podcast episode we dive into a topic of personalized skincare. Our host Oleksandr is joined by the co-founders of Mitra Bio, Dr. Shakiba Kaveh and Dr. Cristiana Banila. Pharmaceutical and personal care companies have been trying to unlock personalized skincare for decades. Shakiba and Cristiana bring a special key to the table, and it is epigenetics. Tune in into our interview to learn more about: ◦ The founding story of Mitra Bio ◦ The role of genetic and epigenetic factors in skin health ◦ Cracking epigenetic code ◦ Role of reliable models in understanding skin diseases ◦ Skin aging and personalized approaches to reverse it ◦ The future of personalized skincare ◦ Advice to young biotech entrepreneurs from Shakiba and Cristiana

Welcome to the next episode of the Personalized Medicine Podcast. In this episode, we have talked about a variety of topics ranging from exploring space and microgravity for applications in biotechnology and physical science to developing pathogen detection systems. Our guest today is Dr. Daniela Bezdan, the Chief Scientific Officer of Yuri Gravity and co-founder of Poppy. Daniela is also the co-chair at several space-associated organizations such as ISSOP (International Space Standards Operation Procedure) and NASA GeneLabs that foster international cooperation, and support educational citizen science projects. Together with Daniela we discussed: ◦ Evolution of microgravity in biotech ◦ Yuri Gravity and its space mission ◦ Key factors in designing space biotech experiments ◦ Poppy and its pathogen detection system ◦ Challenges of starting a start-up ◦ Advice to budding biotech entrepreneurs ◦ The outlook on the next decade of personalized medicineGet in touch with Daniela: ◦ LinkedIn: Daniela Bezdan ◦ Twitter: @Daniela_Bezdan, @yurigravity, @poppy_health ◦ Web: https://www.yurigravity.com/, https://poppy.com/

Welcome to the next episode of the Personalized Medicine Podcast. On this podcast we have talked extensively about antibody, vaccine and CAR-T cell based approaches to treat cancer. Today we will be talking about a new approach in oncology that is based on invariant Natural Killer T Cells, or iNKTs. Our guest today is Dr. Jennifer Buell, the founder, CEO and President of MiNK Therapeutics and the former President and COO of Agenus. Jennifer has over 25 years of experience in the biopharmaceutical space, having held multiple leadership positions at biotech companies. In her tenure at Agenus, she transformed a neoantigen vaccine development startup into a multifaceted company with a strong global footing. She is now leading MiNK therapeutics, the precision oncology company that develops targeted iNKT cells for treatment of various types of cancer and autoimmune diseases. Together with Jennifer we discussed: ◦ Evolution of immunooncology over the the last two decades ◦ Role of immune system in fighting cancer ◦ Neoantigen vaccines as a tool for personalized cancer treatment ◦ Invariant Natural Killer T Cells (iNKTs) and their role in combating cancer ◦ Advantage of iNKTs over other cancer treatments ◦ Potential of combination therapies in oncology ◦ Challenges in bringing novel cell-based therapies to the market ◦ Advice to budding biotech entrepreneurs ◦ The outlook on the next decade of cancer treatmentGet in touch with Jennifer:LinkedIn: Jennifer S. BuellTwitter: @jbuell01Web: https://minktherapeutics.com/

In this episode we dive deep again into the topic of protein degradation and how it can be leveraged to treat neurodegenerative diseases. Our guest today is Dr. Beth Hoffman, the founder, CEO and President to Origami Therapeutics. Beth's career is a showcase of remarkable success in the biotech industry. She spent almost 25 years working in CNS drug discovery and was involved in the development of over 30 therapeutic molecules. Most notably she led the discovery and development of a few first-in-class blockbuster drugs for cystic fibrosis at Vertex Pharmaceuticals. Her most recent venture, Origami Therapeutics, is focusing on developing protein degraders aiming at neurodegenerative disorders and, specifically, Huntington's Disease.Together with Beth we discussed: ◦ The evolution of drug discovery & development over the last 30 years ◦ How protein degraders work ◦ Role of protein structure prediction algorithms in therapy design ◦ Possibility of using targeted protein degradation for treatment of Huntington's diseases ◦ Differences between treating familial vs sporadic neurodegenerative disorders ◦ The future of personalized medicine ◦ Actionable advice for young biotech entrepreneursMake sure to download the full show notes with our guest's bio, links to their most notable work, and our recommendations for further reads on the topic of the episode at pmedcast.com

Thank you very much for tuning into this special episode of the Personalized Medicine Podcast. Some of you might know that our founder and host Oleksandr (a.k.a. Sasha) is Ukrainian. In this difficult moment for his country, Sasha shares his thoughts on current situation in Ukraine and explains how anyone in the world can help and support people of Ukraine and its scientific community.Out team has prepared a list of trusted organizations and charitable foundations supporting Ukraine at the moment:Support Ukrainian military (Official Bank Account of Ukrainian Ministry of Defense): https://bit.ly/35Kl4GyHumanitarian aid organizations providing aid for Ukrainians affected by war: ◦ Ukraine Humanitarian Fund managed by United Nations https://crisisrelief.un.org/t/ukraine - The Ukraine Humanitarian Fund is one of the UN's country-based pooled funds. Contributions are collected into a single, unearmarked fund and managed locally under UN leadership. As crises evolve, funds are made directly and immediately available to a wide range of partner organizations at the front lines of response. This way, funding reaches the people most in need when they need it ◦ Voices of Children - https://voices.org.ua/en/ - Charitable Foundation Voices of Children helps children affected by the war in (eastern) Ukraine. They provide psychological and psychosocial support to children. It helps them overcome the consequences of armed conflict ◦ Vostok-SOS - https://vostok-sos.org/en/ - Non-profit organization focused on comprehensive assistance to conflict-affected persons and IDPs, promoting democratic transformation and human rights values in UkraineIf you would like to host a refugee, you can register at one of the following platforms: ◦ https://www.eu4ua.org/ ◦ https://www.unterkunft-ukraine.de/ ◦ https://www.ukraineshelter.com/en/The global list of research groups and labs that are supporting Ukrainian scientists. Feel free to add your group or share this list with fellow Ukrainian scientists in need of help: https://docs.google.com/spreadsheets/d/1HqTKukfJGpmowQnSh4CoFn3T6HXcNS1T1pK-Xx9CknQ/edit?usp=sharingThank you very much for your support! You are awesome!Stay safePeace

In this episode we are returning to a very exciting topic of immunooncology and we will talk in detail about novel approaches to treat cancer, based on CAR-T cell technology.Please welcome Dr. Eric von Hofe, the Senior Advisor and former President of Affyimmune Therapeutics. Eric's story is a showcase of a remarkable career in the biotech industry. Eric studied Biology at UC Berkeley and received his PhD from the University of Southern California. HEric continued his career in cancer research doing two PostDocs at ETH Zurich and Harvard and then taking a position of Assistant Professor at the University of Massachusetts Medical School. In 1992 Eric made a transition to the biopharmaceutical industry leading the development of antisense oligonucleotide therapies at Hybridon. Eric subsequently led multidisciplinary drug development programs at Millennium Pharmaceuticals as a Director of Drug Discovery Research. Eric has been fundamental for two prominent immuno-oncology companies: Antigen Express, a company focusing on peptide-based cancer vaccines; and Affyimmune Therapeutics, a biotech startup developing novel approaches for CAR-T cell based therapies. With about 50 articles in peer-reviewed journals and four patents Eric is a true expert in the field of oncologyTogether with Eric we discussed:Differences between career in academia and industryEvolution of therapeutic landscape in oncology over the last 30 yearsRole of immunology in development of novel cancer therapiesCAR-T cells and their role in combating cancerAffinity tuning of CAR-T cells as mechanism to decrease off-target effectCancer vaccines: peptide vs mRNAThe future of immunooncologyGet in touch with Eric:LinkedIn: https://www.linkedin.com/in/ericvonhofe/ Email: evhlfe@gmail.comWeb: https://affyimmune.com/ Make sure to download the full show notes with our guest's bio, links to their most notable work, and our recommendations for further reads on the topic of the episode at pmedcast.com

Welcome to the next episode of the Personalized Medicine Podcast. On this show we typically talk about science and technology driving the progress in personalized medicine. But the policy side of things and patient access are equally important.We are happy to welcome on our podcast Christopher Wells, the Vice President of Public Affairs at the Personalized Medicine Coalition. Chris has recently published an article in STAT in which he eloquently described why we cannot narrow down personalized medicine just to cancer and need to look at it through a larger lens. And this is what we have discussed with Chris in this interview.Tune in to this episode to learn more about:Personalized Medicine beyond #genomics and #cancerWhat is the Personalized Medicine Coalition and what are its goals?Difficulties and success stories of bringing healthcare stakeholders togetherThe role of government in driving personalized medicine agendaRole of physician education in implementation of personalized medicine approachesGeneration of reliable clinical data to support personalized medicine implementationChallenge of equal patient access to personalized therapiesThe outlook on the future of personalized medicineGet in touch with Chris:LinkedIn: Christopher Wells, M.P.A. Twitter: @permedcoalition Web: https://www.personalizedmedicinecoalition.org/ Make sure to download the full show notes with our guest's bio, links to their most notable work, and our recommendations for further reads on the topic of the episode at pmedcast.com

Welcome to Season 3 of the Personalized Medicine Podcast! We hope you all head a good start in 2022 and are ready to dive deep into the world of personalized medicine with us again.In this first episode of Season 3, we address a very important and, frankly speaking, underappreciated topic of sepsis, commonly known as bacterial blood poisoning. Did you know that last year, sepsis killed more people than 5 most common types of cancer combined? For this episode, our host Oleksandr Yagensky sat down with the co-founder and CEO of Noscendo, Dr. Philip Stevens. Philip and his team are developing diagnostic workflows based on detection of bacterial and fungal cell-free DNA from blood to detect infections.Listen to this episode to learn more about: ◦ The founding story of Noscendo ◦ Building a successful diagnostics startup in Europe ◦ Generation of clinical evidence for early stage startups ◦ Misconceptions about sepsis and sepsis diagnostics ◦ How NGS can help detect sepsis early ◦ Role of DNA sequencing in determining antibiotic resistance ◦ Philip's advice to aspiring life science entrepreneursGet in touch with Philip: ◦ LinkedIn: https://www.linkedin.com/in/philip-stevens-4ab68213b/ ◦ Twitter: https://twitter.com/noscendo ◦ Web: https://noscendo.com/Make sure to download the full show notes with our guest's bio, links to their most notable work, and our recommendations for further reads on the topic of the episode at pmedcast.com

Welcome to the final episode of 2021! This one was long in the making. We are happy to present the crossover episode between the Genetics Podcast and the Personalized Medicine Podcast. In this episode our host Oleksandr (Sasha) Yagensky wraps up 2021 with one and only Patrick Short, the CEO of Sano Genetics and host of the Genetics Podcast. Listen to Patrick and Sasha as they share their 2021 highlights from the world of Personalized Medicine.Together with Patrick we focused on 6 highlights in 2021: ◦ Large scale liquid biopsy trial for presymptomatic cancer detection ◦ Whole genome sequencing making its entry into newborn screening programs for rare diseases ◦ Advances in application of autologous iPSCs for treatment of Parkinson's disease ◦ Progress in one-time treatments to reverse genetic disorders ◦ Launch of the first FDA approved diagnostic test based on glycoprotein biomarkers for cancer detection ◦ Rise of AI in drug discovery & developmentListen and let us know if you agree with our list? Which important 2021 event did we miss? Let us know on our Twitter or LinkedIn channels.Make sure to check the Genetics Podcast. Patrick is a fantastic host and puts together great interviews with the thought-leaders in the fields of personalized medicine, rare diseases and genetics research.Download the full show notes with our guest's bio, links to their most notable work, and our recommendations for further reads on the topic of the episode at pmedcast.com

In this episode of the Personalized Medicine Podcast we are returning to the topic of aging. It is our pleasure to introduce to you the co-founder & CEO of Rejuvenate Bio, Daniel Oliver. Dan studied Mechanical Engineering & Business at Caltech and obtained an MBA from Harvard Business School. After completing his studies, Dan has co-founded several successful companies in very diverse industries. With Rejuvenate Bio Dan and his co-founder Noah Davidsohn are developing new gene therapies to address aging and age-related diseases.In our conversation with Dan we discussed: ◦ The founding story of Rejuvenate Bio ◦ Role of serendipity in founding successful start-ups ◦ George Church and his support in starting Rejuvenate Bio ◦ Gene therapy as a new way to reverse aging ◦ Epigenetic approach to aging ◦ Tackling aging in dogs ◦ Dan's view on the future of aging research ◦ Bias towards action as an important trait of successful startup foundersGet in touch with Dan: ◦ LinkedIn: https://www.linkedin.com/in/danielcoliver/ ◦ Twitter: @DanielCOliver ◦ Web: https://www.rejuvenatebio.com/Make sure to download the full show notes with our guest's bio, links to their most notable work, and our recommendations for further reads on the topic of the episode at pmedcast.com

This is officially one of the most fun episodes of the Personalized Medicine Podcast. This time we sat down not just with one, but with two amazing guests. Please welcome the co-founders of Ochre Bio, Jack O'Meara and Quin Wills. Together we talked about livers, drug development for metabolic diseases and biotech entrepreneurship. This episode is full of funny anecdotes, contrarian ideas and inspirational thoughts. Give it a listen!Together with Jack and Quin we discussed: ◦ Mission of Ochre Bio ◦ Taking a biotech startup off the ground ◦ Differences in building a biotech companies in the US vs Europe ◦ Deep phenomics and its application in decoding liver disorders ◦ In silico models of human diseases ◦ What do we mean when we talk about personalized medicine ◦ How to handle career & professional adviceGet in touch with Jack and Quin: ◦ Twitter: @Jack_O_Meara, @OchreBio, @dnatieclub ◦ LinkedIn: Jack O'Meara, Quin Wills ◦ Website (Ochre Bio): https://www.ochre-bio.com/Make sure to download the full show notes with our guest's bio, links to their most notable work, and our recommendations for further reads on the topic of the episode at pmedcast.com

In this episode we are focusing on cancer, oncolytic viruses and how investor mindset helps building successful biotech companies. Our guest today is Arthur Kuan, the CEO of CG Oncology. Arthur is a molecular biologist by training. After completing his undergraduate training, Arthur started his career as a venture investor working at several prominent Shanghai-based funds focusing on the Healthcare industry. In 2016, Arthur became the CEO of CG Oncology, one of the portfolio companies of Ally Bridge, the investment fund he was working at the time. In this interview, Arhtur shares his story of becoming a CEO and explains the challenges of bringing a promising scientific idea into clinics.Together with Arthur we discussed:◦ Arthur's journey from investor to CEO◦ The place of oncolytic viruses on the map of cancer therapeutics◦ Combinational therapies for cancer◦ Partnerships between emerging biotech startups and large pharma◦ Differences in the mindset between investors and founders◦ What it takes to lead a successful biotech company today◦ Arthur's vision for the future of personalized cancer treatmentGet in touch with Arthur:◦ Twitter: https://twitter.com/cgoncology, https://twitter.com/KuanArthur ◦ LinkedIn: https://www.linkedin.com/in/arthurkuan/ ◦ Web (CG Oncology): https://www.cgoncology.com/Make sure to download the full show notes with our guest's bio, links to their most notable work, and our recommendations for further reads on the topic of the episode at pmedcast.com

In this episode of the Personalized Medicine Podcast we talk about precision oncology with a scientist and serial entrepreneur, Dr. Gang Song. Gang completed his PhD degree in Biochemistry and Molecular Biology at the Shanghai Medical College of Fudan University and then moved to Harvard where he did a PostDoc at the lab of Tim Springer where he was studying structure and function of cell adhesion molecules. Gang has extensive experience in the life science industry working at various positions at IQuum, which was acquired by Roche, Genzyme Genetics and LabCorp. In 2014, Gang founded Pillar Biosciences, a precision medicine company developing genomics tests for various types of cancer. Gang also co-founded another venture, AffyImmune Therapeutics which is focusing on developing novel cell therapies for cancer based on CAR-T technologies.Together with Gang we discussed:◦ His career from PhD in China to founding multiple successful biotech companies in the US◦ Mentorship lessons from Professor Tim Springer◦ Founding story of Pillar Biosciences◦ Novel NGS approaches for early cancer detection◦ Differences in business models pursued by diagnostics companies in oncology◦ Next generation of CAR-T cell therapeutics◦ Future of precision oncology◦ Gang's advice to aspiring biotech entrepreneursGet in touch with Gang: ◦ LinkedIn: Gang Song, Pillar Biosciences, Affyimmune ◦ Twitter: @pillar_bio, @affyimmune ◦ Web: https://affyimmune.com/, https://pillar-biosciences.com/ Make sure to download the full show notes with our guest's bio, links to their most notable work, and our recommendations for further reads on the topic of the episode at pmedcast.com

On this episode we take a look at the role induced Pluripotent Stem Cells (iPSCs) are playing in drug discovery and development for neurodegenerative diseases. Our host Oleksandr sat down with Professor Evangelos Kiskinis, who is leading his own research group at the Northwestern University in Chicago. Evangelos and his team are leading the way on the development of novel cell-based models for ALS, epilepsy and other types of neurological conditions.Check out this episode to learn more about:◦ Evangelos's career story and what got him excited in stem cell research◦ Challenges in modeling neurodegenerative diseases in a dish◦ iPSC based models for inherited vs sporadic diseases◦ Transitioning promising in vitro discoveries into clinical trials◦ iPSC based cell replacement therapies for Parkinsons and Alzheimers disease◦ The future of iPSC based models in drug discovery◦ Evangelos's advice to young scientists pursuing academic career◦ Get in touch with Evangelos:◦ LinkedIn: Evangelos Kiskinis ◦ Web: http://evangeloskiskinislab.org/index.htmlMake sure to download the full show notes with our guest's bio, links to their most notable work, and our recommendations for further reads on the topic of the episode at pmedcast.com

In this episode, we are diving deep into the world of the non-coding genome and, more specifically, an exciting new class of biomolecules - the long non-coding RNAs (lncRNA). Welcome, Dr. Samir Ounzain, the co-founder and CEO of HAYA Therapeutics. Samir and his startup HAYA are developing first-in-class therapies to target lncRNA responsible for the manifestation of various diseases. Samir and HAYA are aiming at fibrosis first, but have in mind a plethora of other conditions that can be treated by their approach. Join us for an insightful conversation on the non-coding genome, the journey from basic science to entrepreneurship, and the future of precision therapeutics.Together with Samir, we discussed:◦ The founding story of HAYA Therapeutics◦ The role of non-coding genome in human health◦ Ability to tweak non-coding genome to treat diseases◦ Postponing aging using lncRNAs◦ Impact on the future of precision medicine◦ Prerequisites for founding a successful biotech companyGet in touch with Samir:◦ LinkedIn: https://www.linkedin.com/in/samirounzain/◦ Twitter: @ispiyou◦ Website: https://www.hayatx.com/Make sure to download the full show notes with our guest's bio, links to their most notable work, and our recommendations for further reads on the topic of the episode at pmedcast.com

In this Podcast episode we return to the topic of stem cells. We discussed that autologous stem cells can be a powerful therapeutic tool for Parkinson's disease in our interview with Professor Jeanne Loring. The challenge however is to manufacture those therapies at scale. Our guest on this episode is taking a major step in alleviating this hurdle. Meet Nabiha Saklayen, the co-founder and CEO of Cellino, a company that merges stem cell biology, laser physics and machine learning to make autologous stem cell therapies possible. Together with Nabiha, we discussed:◦ Her personal career story from physics to biotech◦ Role of finding product/market fit early in a deep tech startup journey◦ Importance of founding team for any startup◦ Challenges in manufacturing of autologous cell therapeutics◦ Cellino's approach for automated selection and expansion of iPSCs◦ Applications of stem cells in drug discovery◦ The future of personalized stem cell therapiesGet in touch with Nabiha:◦ LinkedIn: https://www.linkedin.com/in/nabihasaklayen/◦ Twitter: @nabsicle ◦ Website (Cellino): https://www.cellinobio.com/Make sure to download the full show notes with our guest's bio, links to their most notable work, and our recommendations for further reads on the topic of the episode at pmedcast.com

This Podcast episode cannot get any closer to what personalized medicine is really about. Welcome Dr. Dan Rhodes, the founder and CEO of Strata Oncology, a leading precision oncology company leveraging state-of-the art genomics tools for more efficient cancer diagnostics and treatment. Dan is a bioinformatician by training and spent his entire career applying genomics to solving complex problems in oncology. Dan founded two very successful startups in this field and also has gathered vast experience working as a VP of Oncology Strategy at large corporations (Life Technologies and Thermo Fisher). This interview is full of deep insights on the state of genomic testing in cancer treatment and reflections on the future of precision oncology.◦ Tune into this episode to learn more about:◦ Dan's journey from a PhD student to a serial biotech entrepreneur◦ Differences between working in a small start-up vs large organizations◦ Strata's mission to determine best possible treatment for each cancer patient◦ Role of RNAseq in precision oncology◦ Approaches for highly-sensitive NGS of solid tumors◦ Paradigm shift in clinical trials for personalized therapeutics◦ Reimbursement landscape in cancer genomics◦ Potential of asymptomatic NGS screening in oncology◦ Dan's vision for the future of precision oncologyMake sure to download the full show notes with our guest's bio, links to their most notable work, and our recommendations for further reads on the topic of the episode at pmedcast.com

In this episode, we return to our beloved field of proteomics. This time we focus on answering a question on how automation and AI can improve biomarker discovery and ultimately benefit patients. Our guest is Dr. Sophia Doll, co-founder of OmicEra Diagnostics, one of the most exciting startups in the field of proteomics today.Sophia did her Ph.D. at the Max Planck Institute for Biochemistry in Munich where she studied translational protein biomarkers of cancer in the lab of Mathias Mann. She conducted part of her graduate research at the University of California in San Francisco and worked for Genentech where she analyzed epigenetic and proteomic alterations in lymphoma. In 2019 Sophia started OmicEra Diagnostics and together with her co-founders they aim at maximizing insights that we can obtain from analyzing various biological samples.Together with Sophia, we discussed:◦ Sophia’s motivation behind starting OmicEra Diagnostics◦ Rise of open-source tools for analysis of omic data◦ Role of protein biomarkers in diagnostics of the future◦ Technological advancement in mass spec based proteomics◦ Struggles in biomarker discovery◦ How proteomics can help us understand the severity of COVID◦ The upcoming developments in the field of mass spec-based proteomics◦ Sophia’s advice to young biotech foundersMake sure to download the full show notes with our guest's bio, links to their most notable work, and our recommendations for further reads on the topic of the episode at pmedcast.com

In this episode we talk about multiple sclerosis (MS) and the role personalized medicine and real world data (RWD) are playing in treating this disease effectively. To discuss this topic, we sat down with one of the leading experts in this field - Dr. Rick Rudick. Rick is a neurologist by training and has more than 25 years of experience at Cleveland Clinic where he developed and directed the Mellen Center for Multiple Sclerosis. Rick was also a Vice President of pharmaceutical company Biogen, where he developed the Multiple Sclerosis Innovation Hub and was involved in establishing international Multiple Sclerosis Partners Advancing Technology and Health Solutions (MS PATHS) program. With about 250 peer-reviewed publications, Rick is one of the most cited researchers in the field.Together with Rick we discussed:◦ Disease-modifying therapeutics for MS◦ Role of RWD & RWE in determining most efficient treatment for MS◦ Establishment of world’s largest learning health system for MS (MS PATHS)◦ Role of international cooperation in standardizing patient care◦ Challenges in collection and processing of diverse patient data◦ Role of MRI in MS diagnostics◦ Translation of novel diagnostic approaches from research to clinics◦ The future of therapeutics for neurological diseasesGet in touch with Rick:◦ LinkedIn: https://www.linkedin.com/in/richard-rudick-966501a5/◦ Web (MS-PATHS program): https://www.mspaths.com/Make sure to download the full show notes with our guest's bio, links to their most notable work, and our recommendations for further reads on the topic of the episode at pmedcast.com

Scientists today still spend an enormous amount of time on physical labor: pipetting, feeding cells, taking microscope images and performing all kinds of other experiments manually. That leaves researchers with a very limited time to do their core activities such as reading, talking to their colleagues and coming up with new hypotheses. Our guest on this episode is coming from an organization that is aiming to change that. Welcome on the show Toby Blackburn, the Head of Business Development and Strategy at Emerald Cloud Lab (ECL). ECL has built a lab that can be accessed virtually by any scientist from any corner of the world to perform specific experiments by simply designing and programming them via an online interface. In this episode Toby explains how the ECL lab works and how cloud based lab solutions are going to shape the future of R&D in pharma and life science industries.Together with Toby we discussed:◦ Need for automation and reproducibility in biomedical research◦ The advent of cloud labs in the biotech industry◦ Advantages that cloud labs can offer scientists around the globe◦ Using AI and ML to optimize experimental workflows◦ Facilitation of research collaborations with cloud technology◦ Pharma R&D in the age of COVID◦ The role of cloud labs in drug manufacturing◦ Industrial applications of cloud labs beyond biotech◦ Outlook on the future of experimentation in life sciencesGet in touch with Toby:◦ LinkedIn: https://www.linkedin.com/in/tobiasblackburn/◦ Web (ECL): https://www.emeraldcloudlab.com/

In this episode of the Personalized Medicine Podcast, we sat down with the guru of bioinformatics, Dr. John Castle. John is a physicist by training who found a passion for answering complex questions in drug development using a data-driven approach. He led bioinformatics teams at multiple successful companies including Rosetta Inpharmatics, Merck and Agenus. John was also employee number 5 at BioNTech, a company best known for its development of the first approved COVID vaccine. While at BioNTech John established and led the Computational Medicine team that was focusing on anti-cancer mRNA-based vaccines. Currently, John is a Chief Data Scientist Officer at Monte Rosa Therapeutics, where he helps the company develop their novel therapeutic approach based on targeted protein degradation.This episode is full of inspirational moments and funny anecdotes. Make sure to check it out. Together with John we discussed: ° Targeted protein degradation as a new approach in the pharma industry ° Combining genomics and protein structure data in drug development ° AlphaFold and progress in deciphering 3D protein structure ° Using bioinformatics to develop more efficient monoclonal antibodies ° Advantages of bispecific antibodies in oncology ° Early days of BioNTech ° mRNA vaccines for the treatment of cancer and infectious diseases ° Differences between doing science in Europe and the US ° Advice to aspiring bioinformaticiansGet in touch with John: ° Linkedin: https://www.linkedin.com/in/john-castle-b1a1458/ ° Twitter: @joccastle ° Web (Monte Rosa): https://www.monterosatx.com Make sure to download the full show notes with our guest's bio, links to their most notable work, and our recommendations for further reads on the topic of the episode at pmedcast.com

In this episode, our host Aradhana Chopra sat down with Leo Martinez, one of the co-founders of Colorimetrix, the mobile health tech company behind the Pearl Fertility app. It is the first App to be approved as a medical device to monitor and chart all-important hormones of the menstrual cycle at home and help women with their fertility decisions. Dr. Martinez shares his experiences of founding Colorimetrix, developing the algorithms, using the technology in the pearl fertility app, and finally getting permissions and approvals for its release in the markets.Together with Leo, we discussed: ° Smartphones as portable spectrophotometers ° Pearl Fertility app and its motivation ° Difference between Pearl Fertility and other similar apps ° Pearl Fertility – compatibility with different strips ° Pearl Fertility app and privacy of users ° Pearl Fertility app – informative or diagnostic ° Timeline for results from the Pearl Fertility app and kit ° Updates to the Pearl Fertility app - test for progesterone ° Demographic coverage of the Pearl Fertility app ° Challenges in developing the app ° Role of science in becoming a successful entrepreneur ° Getting funding for a startup ° Pearl Fertility in the next 10 yearsGet in touch with Leo: ° Email: leo@colorimetrix.com, leo@pearl-fertility.com ° Dr. Leo Martinez’s social handles: ° Twitter: @expecttoexpect ° Instagram: @dr.leomartinez ° Twitter: @pearlfertility, @Colorimetrix ° LinkedIn: https://www.linkedin.com/company/colorimetrix/, https://www.linkedin.com/in/juanleonardo/ ° Web (Colorimetrix): https://www.colorimetrix.com/, https://www.pearl-fertility.com/Make sure to download the full show notes with our guest's bio, links to their most notable work, and our recommendations for further reads on the topic of the episode at pmedcast.com

Welcome to the first episode of the Personalized Medicine Podcast in 2021. And what a guest do we have to kick-off this year!In this episode, we dive deep into the world of stem cells with one of the most influential scientists in the field, Professor Jeanne Loring. Jeanne is a Professor Emeritus and a Director of the Center for Regenerative Medicine at Scripps Research. She made pivotal contributions to the field of stem cell research publishing 120+ papers on the topic. Jeanne is also a true veteran of the biotech industry working for some of the most important companies in the domain of stem cell therapeutics. Jeanne’s most recent venture is Aspen Neuroscience, a pharmaceutical company that develops cell replacement therapies for Parkinson’s disease based on a patient’s own induced pluripotent stem cells (iPSCs).This episode is full of inspirational moments from Jeanne as she shares her experiences differentiating her own cells into beating cardiomyocytes and witnessing the delivery of organoids prepared in her lab to the International Space Station.Together with Jeanne we discussed: ° Application of iPSCs in the treatment of Parkinson’s disease ° The founding story of Aspen Neuroscience ° Unexpected cost advantage of autologous vs allogeneic iPSCs ° Delivery systems for stem cell therapies ° Use of next-generation sequencing in quality control of stem cell therapies ° Logistics challenges in making iPSC-based therapies available ° Growing organoids at the International Space Station ° Future applications of iPSCs in drug screening and cell-replacement therapiesMake sure to listen until the very end of the episode, when Jeanne shares some very practical advice for aspiring young scientists.Get in touch with Jeanne: ° LinkedIn: Jeanne Loring ° Twitter: @jeannefrances, @AspenNeuro ° Web: https://www.aspenneuroscience.com/Make sure to download the full show notes with our guest's bio, links to their most notable work, and our recommendations for further reads on the topic of the episode at pmedcast.com

In Episode 3 of Season 2 of the Personalized Medicine Podcast, our new host, Aradhana Chopra, sat down with Dr. Cosimo Ducani. Cosimo is the founder and CEO of Moligo Technologies, a Biotech start-up from Sweden that aims at providing alternative and improved enzymatic nucleic acid synthesis methods at the industrial scale. Cosimo talks about the increasing demand and need for long and ultra-pure DNA strands in diagnostics and therapeutics and explains oportunities and challenges young biotech start-ups are facing on their journey to success.Together with Cosimo we talk about: ◦ What inspired Cosimo to start his own company ◦ Key focus areas of Moligo Technologies ◦ How can Moligo Technologies contribute towards personalized medicine and the development of nucleic acid-based vaccines ◦ Professor privilege and role of start-up incubators in early stage biotech ventures ◦ Positives of a lab & of a start-up setup ◦ Advice that Cosimo the CEO would give to Cosimo the scientist and vice-versa ◦ Cosimo’s tips to budding entrepreneurs ◦ Future of DNA-based therapeuticsGet in touch with Cosimo: ◦ Linkedin: Cosimo Ducani, Moligo Technologies ◦ Twitter: @CosimoDucani, @moligotech ◦ Web: https://www.moligotechnologies.com/Make sure to download the full show notes with our guest's bio, links to their most notable work, and our recommendations for further reads on the topic of the episode at pmedcast.com

The next episode of the Personalized Medicine Podcast is out! In this episode we take a look at the role of genetic factors in the development of neurological disorders. Our host Oleksandr Yagensky sat down with one of the gurus of the field, Prof. Naomi Wray. Naomi holds joint appointments at the Institute for Molecular Bioscience (IMB) and the Queensland Brain Institute (QBI) within the University of Queensland. She has published around 300 papers on the intersection of neurobiology, genetics and bioinformatics and contributed greatly to our understanding of genetic causes of schizophrenia, depression and many other neurological disorders.Together with Naomi, we talk about: ◦ Naomi's motivation to get into the field of psychiatric diseases and genetics ◦ What are polygenic risk scores and how can they be determined? ◦ How can polygenic risk scores be used in the context of psychiatry? ◦ Increasing the utility of polygenic risk scores in clinical settings ◦ Identification of appropriate therapeutic strategy for specific psychiatric conditions based on patient's genetic background ◦ Ethical considerations around communicating genetic predisposition for diseases to patients ◦ Future of neurobiology research ◦ Importance of collaboration in research ◦ Naomi's advice to young scientists starting out their academic careerGet in touch with Naomi: ◦ Twitter: @WrayNaomi ◦ Web (UQ webpage): Naomi WrayMake sure to download the full show notes with our guest's bio, links to their most notable work, and our recommendations for further reads on the topic of the episode at pmedcast.com

We are back! The first episode of Season 2 of the Personalized Medicine Podcast is out! In this episode, our host Oleksandr Yagensky sat down with Dr. Oliver Rinner, co-founder, and CEO of Biognosys, a proteomics technology company. We discussed the growing role of proteomics in healthcare, its impact on biomarker discovery, and the development of new therapeutics. Together with Oliver, we talk about: ◦ Startup story of Biognosys ◦ Transitioning from academia to entrepreneurship ◦ Impact of proteomics on pharma industry ◦ Role of proteomics in biomarker discovery ◦ Differences between targeted and discovery mass spectrometry ◦ Role of AI and ML in the analysis of OMICs data ◦ How can proteomics take up a mainstream role in clinical diagnostics? ◦ The outlook on the personalized medicine of the futureGet in touch with Oliver: ◦ Twitter: @oliverrinner, @biognosys ◦ Linkedin: https://www.linkedin.com/in/orinner/  ◦ Web: https://biognosys.com/Make sure to download the full show notes with our guest's bio, links to their most notable work, and our recommendations for further reads on the topic of the episode at pmedcast.com

Welcome to the final episode of Season 1 of the Personalized Medicine Podcast!In this episode we look back at the past 9 months, share our own story and remember the most exciting moments of season 1. Our entire team has joined for the recording to share and discuss what we have learned from our guests. We have covered a broad range of topics spanning from genomics to artificial intelligence to privacy-by-design. As we look back, we tie in the insights we have gained from each and every speaker we had a privilege to welcome on our show.Together with the team, the hosts Oleksander and Luisa discuss: ◦Start-up story of our Podcast ◦Our unforgettable podcast moments ◦Three Drivers of Precision Medicine ◦Technological advances in Precision Medicine ◦The need and importance of data integration ◦Our perspective on AI and ML ◦Ethics, privacy and policy in Personalized Medicine ◦Entrepreneurship within healthcare space ◦The importance of stakeholder engagementGet in touch with us: ◦ Twitter: @PMedCast ◦ LinkedIn: https://www.linkedin.com/company/30742354 ◦ Facebook: https://www.facebook.com/PMedCast ◦ Email: team@pmedcast.comMake sure to vote in our call-to-action on social media and download the full show notes with the geolocation of our audience and all 16 speakers at our website pmedcast.com.

Precision medicine has the potential to transform healthcare in terms of diagnostics, treatment and prevention of disease. But what does a future with a more personalized approach to medicine look like? Who will ultimately benefit from precision medicine?In this episode, we dive into these questions with Dr. Kadija Ferryman, a cultural anthropologist whose research centers on the ethical dimensions of health risk technologies, especially as they relate to racial disparities in health. Kadija is an Industry Assistant Professor at NYU’s Tandon School of Engineering. She is also an affiliate at the Data & Society Research Institute, where she led a research study on Fairness in Precision Medicine. This ground-breaking study examined the potential for biased and discriminatory outcomes in the emerging field of precision medicine.Together with Kadija, we talk about: ◦ BiDil: the first FDA-approved drug marketed to a single racial-ethnic group ◦ The promise and potential of precision medicine ◦ The 'Fairness in Precision Medicine' study ◦ The need for proactive ethical studies ◦ Bias in how we collect and examine electronic health data ◦ Bias in medical outcomes due to existing patterns of marginalization ◦ Human bias in AI and Machine Learning ◦ Implicit bias in healthcare professionals ◦ Establishing a more equitable medical futureGet in touch with Kadija: ◦ Twitter: @KadijaFerryman ◦ Web: http://www.kadijaferryman.com ◦ Web (Data & Society): https://datasociety.net/people/ferryman-kadija/ ◦ Web (CRDS): https://criticalracedigitalstudies.comMake sure to download the full show notes with our guest's bio, links to their most notable work, and our recommendations for further reads on the topic of the episode at pmedcast.com

In episode 15, our host Oleksandr Yagensky sat down with Dr. Liz O’Day, the founder and CEO of Olaris, a biotech company that enables patients to pursue most effective personalized treatments. Liz unravels how small molecule metabolites along with machine learning can be utilized to evaluate patient-specific responses to therapeutics. Together with Olaris, Liz is shaping the future of personalized medicine. Just two weeks ago, she was elected to the Board of Directors at Personalized Medicine Coalition in recognition of her contribution to the field.Together with Liz, we discussed: ◦ The startup story of Olaris ◦ Biomarkers of Response (BORs) ◦ The future of biomarker panels and multi-omics ◦ Metabolite based biomarker profiling ◦ Analytical platforms used at Olaris ◦ How Olaris leverages machine-learning to find patient-specific metabolite patterns ◦ Application cases for Olaris technology in cancer treatment ◦ Three part aim of Olaris ◦ Bringing the stakeholders in healthcare together ◦ Role of science in becoming a successful entrepreneur ◦ Common challenges faced by biotech start-ups ◦ The future of personalized medicineGet in touch with Liz: ◦ LinkedIn: @Liz O'Day ◦ Twitter: @Lizzard0126 ◦ Facebook: https://www.facebook.com/olarisBoR/ ◦ Instagram: https://www.instagram.com/lizzard0126/ ◦ Web: https://www.olarisbor.com/Make sure to download the full show notes with our guest's bio, links to their most notable work, and our recommendations for further reads on the topic of the episode at pmedcast.com

Recently glycans have been receiving a lot of attention. It turns out, the surface of coronavirus is packed with glycans, which help this virus evade our immune system.In this episode, we interviewed Dr. Parastoo Azadi, whose recent research sheds light on the structure of coronavirus core surface glycoprotein, and hence can facilitate the development of a vaccine against it.Together with Parastoo, we have discussed: ◦ Role of glycans in coronavirus infection ◦ Challenges in developing an effective vaccine against SARS-COV-2 ◦ Significance of glycobiology in the biotech industry ◦ Evolution of Mass Spectrometry ◦ NMR vs MassSpec in studying protein glycosylation ◦ Approaches to decipher glycan structures on the surface of proteins ◦ Role of glycan biomarkers in personalized medicine ◦ Improving antibody-based therapeutics with glycoengineering ◦ The future of glycobiologyGet in touch with Parastoo:Twitter: @CCRCUGALinkedIn: Parastoo AzadiWeb (Complex Carbohydrate Research Center):https://ast.uga.edu/Make sure to download the full show notes with our guest's bio, links to their most notable work, and our recommendations for further reads on the topic of the episode at pmedcast.com

In thirteen episode of the Personalized Medicine Podcast we focus on the personalization oftreatment in clinical practice. There is mourning evidence that shows that variations in thegenome can significantly affect inter-patient differences in drug response. Together with AmaniSaini, the founder of Adverse Drug Reaction (ADR) Canada, we talk about the field ofpharmacogenomics, adverse drug reactions and the future of tailored therapy. Amani holds aBA in Political Science from the University of British Columbia and Master of PublicAdministration degree from Dalhousie University. She currently serves as president of ADRCanada, which brings together patients, researchers, and policymakers to advocate for theincreased the use of genomics in guiding health decisions.Together with Amani, we talked about: ◦ The start-up story of ADR Canada ◦ The burden of adverse drug reactions ◦ The effectiveness of clinical trials ◦ Known gene variants that influence responses to drugs ◦ Genomics as a tool to prescribe effective, safe medications ◦ Advances in pharmacogenomics around the world ◦ The benefit of mandatory healthcare databases ◦ Improving reporting structures in healthcare ◦ The policy proposals of ADR Canada ◦ Turning scientific discovery into clinical practice ◦ The stakeholders in healthcare policy ◦ Future plans for ADR Canada ◦ Science communication, education, collaboration ◦ The future of pharmacogenomicsGet in touch with Amani:Twitter: @amani_sainiTwitter (Adverse Drug Reaction Canada): @adr_canadaWeb (Adverse Drug Reaction Canada): https://adrcanada.orgMake sure to download the full show notes with our guest's bio, links to their most notable work, and our recommendations for further reads on the topic of the episode at pmedcast.com

In Episode 12, we discuss the progress of personalization in the field of reproductive medicine with our guest Dr. Helen O'Neill. Helen is a Lecturer in Reproductive and Molecular Genetics and Director for the MSc Program in Reproductive Science and Women’s Health at the Institute for Women’s Health, University College London. She has over 10 years of experience as a researcher and science communicator on various topics of reproductive medicine, genome editing, and women’s health. Beyond her work as an academic, she recently co-founded Hertility Health with the aim to change the face of women’s health.Our host Luisa talked to Helen about: ◦ The importance of reproductive health ◦ The power of genome editing ◦ CRISPR as a collection of technologies ◦ Ethical concerns around genome editing ◦ Using sequencing to examine embryo development ◦ Gene editing in clinical settings ◦ Start-up story of Hertility Health ◦ Why women's health research is still in its infancy ◦ The need for open science communication ◦ Including men in fertility education ◦ Launching a start-up during COVID-19 ◦ Improving women's health through more research ◦ The future of personalized medicine in reproductive healthGet in touch with Helen:UCL Iris profile: Helen O NeillTwitter: @DrHelenONeillLinkedIn: Dr Helen O' NeillInstagram @dr.helenoneillWeb: https://hertilityhealth.com/Make sure to download the full show notes with our guest's bio, links to their most notable work, and our recommendations for further reads on the topic of the episode at pmedcast.com

In Episode 11 of the Personalized Medicine Podcast our host Oleksandr Yagensky discussed the topic of genetic data management with Dr. Mark Hahnel. Mark is the co-founder of Genomes.io, a personalized DNA databank that gives consumers ultimate control of their genome data. He is also CEO and founder of Figshare, repository for published and unpublished scientific data of all formats.Together with Mark, we discussed: ◦ The importance of open access in research acceleration ◦ A new approach Genomes.io is applying to consumer genomics ◦ Role of blockchain in DNA data security ◦ How consumers can monetize their own genetic data ◦ Benefits of genetic testing for consumers ◦ Advancing personalized medicine with a widespread genome sequencing ◦ Using genetic data for personalized drug development ◦ Convincing venture capital firms to invest in your life science company ◦ The future of consumer genomicsGet in touch with Mark:Twitter: @MarkHahnelLinkedin: Mark HahnelWeb: https://genomes.io/Web: https://figshare.com/Make sure to download the full show notes with our guest's bio, links to their most notable work, and our recommendations for further reads on the topic of the episode at pmedcast.com

In the tenth episode of the Personalized Medicine Podcast, we talk about digital health technology in Rwanda. Our host Luisa Hallmaier-Wacker talks to Dr. Patrick Singa, the medical director babyl, about telehealth and the integration of AI into clinical diagnostics. Babylon Health, which is based in the UK, launched babyl in 2016 in Rwanda and established a comprehensive fully integrated mobile healthcare service. With over 2 million registered users and over 3,500 consultations a day, babyl has been very successful to date and is currently working on integrating AI technology into clinical diagnostics. Patrick has been involved with babyl since its inception. He has over 10 years of hands-on medical experience and has held different positions within the Rwandan ministry of health as well as the United Nations. Patrick has leveraged his extensive experience and passion for public health to drive the integration of digital health technology to improve patient care in Rwanda and beyond.Together with Patrick, we discussed: ◦ Rwanda as a pioneer in digital health in Africa ◦ The babyl services platform ◦ The social impact of babyl ◦ Digital health in UK versus Rwanda ◦ Driving patient adoption of telemedicine ◦ Developing and implementing AI ◦ Testing the accuracy of AI algorithms ◦ How the role of clinicians will evolve ◦ Expansion of babyl service locally and globally ◦ babyl response to novel coronavirus ◦ How COVID19 is changing digital healthGet in touch with Patrick:Twitter: @SingaPatrickLinkedIn: Patrick Singa MuhozaTwitter: @babylrwandaWeb: http://www.babyl.rw/Make sure to download the full show notes with our guest's bio, links to their most notable work, and our recommendations for further reads on the topic of the episode at pmedcast.com

In episode 9 we dive deep into the topic that could not be more relevant today - diagnosis of infectious diseases. Our guest on this episode is Tim Blauwkamp, the co-founder and Chief Scientific Officer of Karius, a company that leverages genomics and AI to develop highly-accurate diagnostic tests based on cell-free DNA sequencing. Karius has recently raised a stunning Series B round of $165 million to further the transition of their test to clinic.Tim did his PhD in Biochemistry at the University of Michigan, where he studied genes involved in nitrogen assimilation in bacteria. He then continued as a PostDoc first in Michigan and then at Stanford researching the mechanisms behind WNT signaling and its role in cell differentiation. He then joined Moleculo as a Head of Molecular biology. Moleculo was acquired by Illumina and Tim was responsible for bringing to life the technologies that made it possible to generate long and accurate sequencing reads. About six years ago, Tim co-founded Karius together with Mickey Kertesz. Tim and his team have achieved enormous progress during the last years, bringing the diagnostic tests to clinics that are already changing the lives of patients. Together with Tim, we have talked about:: ◦ The story behind Karius ◦ Cell-free DNA (cfDNA) as a blood biomarker of infection ◦ Why DNA sequencing has an edge over classical microbiology methods ◦ The challenge of isolating microbial cfDNA from blood ◦ Untangling cfDNA sequencing data with AI ◦ Why Coronavirus (SARS-CoV-2) is hard to detect using NGS ◦ Diagnosing sepsis based on microbial cfDNA ◦ Clinical evidence as a key to healthcare innovation ◦ Working with payers to spread the use of innovative diagnostic tests ◦ How cfDNA screening can become a cornerstone of next-generation medicineGet in touch with Tim: ◦ LinkedIn: Tim Blauwkamp ◦ Twitter: @timblauwkamp ◦ Web (Karius): http://kariusdx.com/ ◦ Email: tim.blauwkamp@kariusdx.comMake sure to download the full show notes with our guest's bio, links to their most notable work and our recommendations for further reads on the topic of the episode at pmedcast.com

In the eighth episode of the Personalized Medicine Podcast we discuss the role of AI in psychiatric treatments with Dr. Maryna Polyakova. Maryna is a medical doctor by training and a scientist who recieved her PhD from the Max Planck Institute for Human Cognitive and Brain Sciences in Leipzig. She is also the CEO and co-founder of AccuBio, a company that enables personalized treatments for depression leveraging AI approaches.Together with Maryna we discussed: ◦ The heterogeneity of depression ◦ Investigation of blood biomarkers for depression ◦ Integration of clinical neuroimaging, proteomic and genomic data ◦ Switching from researcher to entrepreneur, and back ◦ Science and business ◦ How entrepreneurs can transfer their ideas to clinics ◦ What motivates young entrepreneurs starting companies in healthcare (hint: not money) ◦ Why is it hard to find treatment for neurodegenerative diseases ◦ Alzheimer’s disease beyond amyloid theory ◦ The role of personalized medicine in neurological disordersGet in touch with Maryna: ◦ Twitter: @dr_polyakova ◦ LinkedIn: Dr. Maryna Polyakova ◦ Mail: polyakova@cbs.mpg.de ◦ Web (Max Planck Institute): Maryna PolyakovaMake sure to download the full show notes with our guest's bio, links to their most notable work and our recommendations for further reads on the topic of the episode at personalizedmedicinemedia.com

In episode 7 we are addressing a topic that is important in many areas of personalized medicine– data privacy protection, together with Dr. Rachele Hendricks-Sturrup. Rachele is a prominentacademic in the field of consumer privacy and currently serves as a Health Policy Counsel at theFuture of Privacy Forum. The Future of Privacy Forum is a nonprofit organization that aims toexplore the challenges posed by technological innovation and develop privacy protections,ethical norms, and workable business practices together with industry, academics, consumeradvocates, and other thought leaders. The organization ‘fills the void in the space not occupiedby law’ – in fields like personalized medicine which are rapidly evolving technologically. Together with Rachele we have discussed ◦ The aims of Future of Privacy Forum ◦ Privacy challenges in genetic testing services ◦ Best practices around the use of direct-to-consumer genetic testing ◦ Direct-to-consumer genetic testing company selling rights to develop a drug ◦ Striking the balance between privacy and discovery ◦ Privacy challenges in AI and Machine learning ◦ Medical databases in an increasingly digitized healthcare system ◦ The future of privacy and data in personalized medicineGet in touch with Rachele: ◦ Linkedin: @Dr. Rachele Hendricks-Sturrup ◦ Website: www.fpf.org ◦ FPF Blog: https://fpf.org/category/blog/Make sure to download the full show notes with our guest's bio, links to their most notable work and our recommendations for further reads on the topic of the episode at personalizedmedicinemedia.com

In episode 6 we are addressing one of the hottest topics in modern medicine – Immuno Oncology, together with Dr. Stefaan van Gool. Stefaan is a Medical Director of Translational Oncology at the Immunooncological Clinical Center in Cologne, Germany. IOZK is one of the most advanced institutions of this kind in the country. Stefaan has more than 25 years of experience in clinical oncology and related basic research. He has co-authored more than 150 research papers on the relationship between the immune system and cancer.Together with Stefaan we have discussed:◦ The rise of Immuno Oncology◦ How to activate patient’s immune system to fight cancer◦ Personalized treatment of cancer◦ The development of vaccine IO-Vac◦ Advantage of checkpoint inhibition therapy◦ Oncolytic viruses as the anti-tumor agents◦ How to determine the type of therapy for certain cancer◦ Types of tumours most susceptible to immunotherapy◦ The patient journey while treated with IO-Vac◦ Biggest challenges in integrating immunotherapy into routine clinical practice◦ The outlook of the future of personalized medicine and its role in oncologyGet in touch with Stefaan:◦ Linkedin: @Stefaan Van Gool◦ Web (IOZK: https://www.iozk.de/en/)

In the episode 5 we dive deep into the topic of digitalization in personalized healthcare. A lot has been going on in this space lately, especially in Germany. Therefore we are delighted to talk to one of the key opinion leaders on this topic, Professor David Matusiewicz. David is a professor of Healthcare Management at the FOM University for Applied Sciences and is a founding director of the Research Institute for Healthcare Management in Essen, Germany. He co-authored several books on the topics of digitalization and management in healthcare. David is also actively supporting medical startups as an angel investor and in May 2019 he has founded the Digital Health Academy in Berlin.Together with David, we have discussed:◦ What digitalization of healthcare actually means◦ What are the roadblocks to Healthcare 4.0◦ How new legislation is shaping the relationship between patients, providers and payers in Germany◦ The new generation of healthcare startups◦ Data privacy challenges in healthcare◦ Integration of personalized medicine workflows in the healthcare system◦ Digital Health Academy◦ Investing in healthcare startups◦ Bringing entrepreneurs, payers and healthcare providers together◦ Outlook on the healthcare of 2020sGet in touch with David:◦ Twitter: @dmatusiewicz◦ LinkedIn: Prof. Dr. David Matusiewicz◦ Email: david.matusiewicz@gmail.com•Web: https://www.david-matusiewicz.com/•Instagram: @david_matusiewiczMake sure to download the full show notes with our guest's bio, links to their most notable work and our recommendations for further reads on the topic of the episode at personalizedmedicinemedia.com

On the fourth episode of the Personalized Medicine Podcast we switch gears from biomarker research to clinical trials with Christian Erb. Christian is a co-founder and CEO of Mondosano, a Hamburg-based company that addresses the bottleneck for a successful clinical trial – patient recruitment. Listen to our discussion with Christian to learn more about:◦ The story behind the founding of Mondosano ◦ Why clinical trials do not have good reputation among patients◦ Why patient education is the key to improve patient recruitment◦ Patient journey to and through a clinical trial ◦ How Mondosano helps pharma companies and study sites to recruit patients◦ Why most clinical trials fail to finish on time◦ Patient stratification on clinical trials◦ How to prevent patient drop-out◦ Preserving data privacy while recruiting patients and managing trials◦ Three most anticipated developments in the clinical trials space ◦ A way forward for personalized medicineGet in touch with Christian:◦ Twitter: @NTpreneur◦ LinkedIn: Christian Erb◦ Email: christian.erb@mondosano.de◦ Web (Mondosano, German website): https://www.mondosano.de/◦ Web (Mondosano, international website): https://www.mondosano.org/Make sure to download the full show notes with our guest's bio, links to their most notable work and our recommendations for further reads on the topic of the episode at personalizedmedicinemedia.com

In the third episode of the Personalized Medicine Podcast we discuss glycans and their role in personalized medicine with Professor Gordan Lauc. Gordan is a Professor of Biochemistry and Molecular Biology at the University of Zagreb. He is also a Founder and CEO of Genos, one of the few companies in the world capable of high-throughput glycan analysis. In addition to it, Gordan has initiated the Human Glycome Project to facilitate collaboration between laboratories around the world and to encourage more scientists to include glycan analysis in their research. Together with Gordan we have discussed:◦ Why most drugs don’t work in most patients◦ Why glycans can be very precise biomarkers of diseases, aging and inflammation◦ Challenges in the robust measurement of protein glycosylation◦ The Human Glycome Project◦ How individual glycosylation profile can affect treatment outcomes◦ Glycan-engineering to improve the efficiency of monoclonal antibody therapies◦ Patient stratification for clinical trials should take advantage of individual protein glycosylation.◦ Technical challenges of transferring glycan biomarkers from research to clinics◦ How to assess biological age with glycans using GlycanAge test◦ Dynamics of antibody (IgG) glycome◦ Relation between the glycosylation of blood plasma proteins and metabolic diseases◦ Why every biomedical study should include glycan analysis◦ The outlook on the role of glycans in personalized medicineGet in touch with Gordan:Twitter: @GordanLaucWeb (Human Glycome Project): https://human-glycome.org/Make sure to download the full show notes with Gordan's bio, links to his most notable research papers and our recommendations for further reads on the topic of the episode at personalizedmedicinemedia.com

In the second episode of the Personalized Medicine Podcast we dive into the world of genomics with Dr. Rocío Acuña Hidalgo. Rocío is a Chief Technology Officer at Nostos Genomics, a Berlin-based company that develops AI tools to diagnose patients with genetic diseases.Tune into this episode to learn more about:•The role of the Human Genome Project in our understanding of human genes •Impact of the Next Generation Sequencing on genomics •Are rare diseases really rare?•Big data problem in genomics•How machine learning can be leveraged to extract maximum clinical value from genetic data•Applications of genetic testing in personalized medicine•The role of genomics in the future of personalized medicineAccess the full show notes with Rocío's bio, links to her most notable research papers and our recommendations for further reads on the topic of the episode at personalizedmedicinemedia.com

In this episode we discuss the importance of protein biomarkers in clinical diagnostics with Professor Kevin Mills. Kevin is a head of Translational Mass Spectrometry Research Group at University College London and co-authored more than 150 publications in the field of biomarker research. His test for the diagnosis of Fabry disease is used today to screen millions of patients worldwide. Tune into this episode to learn more about:•The evolution of biomarker research•Kevin's test to diagnose Fabry disease•Challenges in translating prospective biomarkers from research to clinics•The role of mass spectrometry in biomarker discovery•Why triple-quad mass spectrometers can replace ELISA tests in clinical labs.•What is the most important "OMICS" area today.•Why machine learning combined with mass spectrometry can be a powerful combination to discover the panels of highly-specific biomarkers.Visit our website personalizedmedicinemedia.com to download the full show notes of this episode that include Kevin's bio, links to his most notable work and additional reads on the topic of the episode.